	f.	MAY	, 8							Sheet 1 of 4		
FORM PRO1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							File No. 02-24		Serial No. 10/691,923			
INFORMATION SISCLOSURE STATEMENT BY APPLICANT								Applicant(s): Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson				
THE THEODOR OF THE PARTY OF THE										oup: 1646		
	,,				1	U.S. PATENT DOCUMEN	ГS		_			
EXAMIN INITIAL	ER		DOCUMENT NUMBER		DATE	Name	CLASS	SUBCLASS		FILING DATE IF APPROPRIATE		
17	4	A1	2003/0104416		06/05/03	Sheppard et al.	435	6				
$ \top $		A2	2004/00293	228	02/12/04	Presnell et al.	435	69.1				
		A3	2002/0039	763	04/04/02	Sheppard et al.	435	69.1				
	$\overline{}$	A4	2004/0138		07/15/04	Klucher et al.	514	12				
		A5	5,206,344		04/27/93	Katre et al.	530	351				
	4											
EXAMIN	nen.	<u> </u>	DOCUMEN		FO	REIGN PATENT DOCUM	ENTS			FILING DATE IF		
INITIAL	EK	ŀ	NUMBER		DATE	COUNTRY	CLASS	SUBCLASS		APPROPRIATE		
	H	A6	03/06600	2	08/14/03	WIPO	\ <u>\</u>	CODCLASS	$\overline{}$	THE ROLL AND		
- ₹		A7	02/08608		10/31/02	WIPO	 \ 	 	/			
		A8	03/08960		10/30/03	WIPO		 				
 		A9	02/20569		03/14/02	WIPO		\				
 		A10	02/09276	2	11/21/02	WIPO		\				
<u> </u>	├	All	0 032 134			EP	 	4-\				
—	- 1		04/037995		07/15/81			 				
<u> </u>	<u>\</u>	A12	04/03/99	<u> </u>	05/06/04	WIPO	+	+		ļ		
ļ		·	OTHER			(Including Author, Title, D						
Kotenko et al., "IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex," Nature Immunology 4(1):69-77, 2003.									eceptor complex,"			
	··-	A14		Shep 2003		-28, II-29 and their class II cytokin	e receptor IL-2	28R," Nature I	mmun	ology 4(1):63-68,		
		Al5 Langer et al., "The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions," Cytokine and Growth Factor Reviews 15:33-48, 2004.										
		A16		Donnelly et al., "The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain," J. Leukocyte Biol. 76:314-321, 2004.								
		Al7		Dumoutier et al., "Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-λ1," J. Biochem. 279(31):32269-32274, 2004.								
1	V	Al8		Univ	versity Calif. S	anta Cruz Genome Browser - Chro	mosome 19, A	pril 20, 2001.				
Exam	Examiner Date considered 1/66/06											
						whether or not citation is in out considered. Include copy	conformance					

applicant.

FORM PTO 1249 C.S. DEPARTMENT OF COMMERCE (REV 2-32) PATENT AND TRADEMARK OFFICE							File No. 02-24 Serial No. 10/691,923				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Cas several sheets if necessary)								Applicant(s): Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson			
1	MAI	U -,					Filing Date: Group: 1646				
V	1	TRA	DEME	<i>y</i>		October 23,	2003				
U.S. PATENT DOCUMENTS											
EXAMI INITIAI				DOCUMENT NUMBER	DATE	Name		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
			_		FOI	REIGN PATEN	NT DOCUM	ENTS			
EXAMI				DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
			((Including Aut	hor, Title, D				
	1 i		A19	Ur	iversity Calif. Sa	anta Cruz Genome E	Browser Databas	se – August 6, 20	001, Accession	n No. C19001210.	
+	H	\dashv	A20	Ur	iversity Calif. Sa	anta Cruz Genome I	Browser Databas	se – August 6, 20	001, Accession	n No. C19001212.	
		\dashv	A21			anta Cruz Genome I					
· '			A22	Un	iversity Calif. Sa	anta Cruz Genome I	Browser Databas	se – December 2	2, 2001, Acce	ssion No. C19001260.	
			A23	Ur	University Calif. Santa Cruz Genome Browser Database – December 22, 2001, Accession No. C19001256.						
	1		A24	Ur	iversity Calif. Sa	anta Cruz Genome J	Browser Databas	se – December 2	2, 2001, Acce	ession No. C19001257.	
	\pm		A25_	En	sembl Contig. V	iew Sanger Institute	e – April 19, 200	01, Accession N	o. AC011445.		
	\pm	\exists	A26	Er	sembl Contig. V	iew Sanger Institute	e – April 18, 20	00, Accession N	o. AC018477.		
	1		A27	Ad	iams et al., "3,40					uman brain," Nat. Genet.	
	\exists				256-267, 1993.						
	-	-	A28	Ge	nBank Submissi	ion XP-002202436,	October 12, 20	00.			
	\Box		A29	Ge	nBank Submissi	ion XP-002202437,	December 12,	1999.			
			A30			'Novel Interferon-Li e Res. 22(1):S-48, 2		ot Recognized b	y the Type I In	nterferon Receptor," J.	
			A31	Ac	lams et al., Acce	ssion No. T07139, 1	1993.				
		\bigvee	A32	D	DE Joint Genome	e Institute Stanford	Human Genome	Center Access	ion No. ACOL	1445, 1999	
								,			
-		ΔI	A33	Mı	izney et al., Acco	ession No. AC0074			····		
Examiner Date considered 1/9/66											
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

FORM PTO 1449 (REV 2-32)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			File No. 02-24		Serial No. 10/691,923			
INFORMA		DISCLOSURE Jse several she		Applicant(s): Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson							
	,			Filing Date: October 23, 2003		Group: 1646					
U.S. PATENT DOCUMENTS											
EXAMINER INITIAL			DATE NAME			CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
•			FOF	REIGN PATENT D	OCUM	ENTS		·			
Examiner Initial		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
		OTHER DOC	UMENTS ((Including Author,	Title, D	ate, Pertiner	t Patents,	etc.)			
FH	A34		iversity of California Santa Cruz database using Softberry, Inc. gene prediction software, Accession No. 9001084, 2001.								
1	A35		Scott et al., "The Pendred syndrome gene encodes a chloride-iodide transport protein," <i>Nature Genetics</i> , 21:440-443, 1999.								
	A36		Korba et al., "A cell culture assay for compounds which inhibit hepatitis B virus replication," Antiviral Research 15:217-228, 1991.								
·	A37	Brac	Brack et al., "Molecular analysis of the human interferon-α gene family," Gene 15:379-394, 1981.								
	A38	Franc biolo	Francis et al., "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques," <i>International Journal of Hematology</i> , 68(1):1-18, 1998.								
	A39	Rajar disso	Rajarathnam et al., "Disulfide Bridges in Interleukin-8 Probed Using Non-Natural Disulfide Analogues: dissociation of Roles in Structure from Function," <i>Biochemistry</i> 38:7653-7658, 1999.								
	A40		Luxon et al., "Pegylated Interferons for the Treatment of Chronic Hepatitis C Infection," Clinical Therapeutics 24(9):13631383, 2002.								
	A41		Kozlowski et al., "Improvements in protein OEGylation: pegylated interferons for treatment of hepatitis C," Journal of Controlled Release 72:217-224, 2001.								
	A42		Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site," Bio/Technology 8(4):343-346, 1990.								
V	A43			ure-Function Studies of Incomology Modeling," J. E				enesis, Polyethylene Glycol			
Examiner Date considered (9 06) EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line											

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (REV 2-32)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			File No. 02	-24	Serial No. 10/691,923			
INFORMA				ESTATEME	Applicant(s): Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson						
					Filing Date: October 23,		Group: 1646				
U.S. PATENT DOCUMENTS											
EXAMINER INITIAL				DATE	Name	·····	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
				FOF	REIGN PATENT	DOCUM	ENTS				
Examiner Initial		DOCUMEN NUMBER	Т	DATE	COUNTRY		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		OTHER	DOC	UMENTS ((Including Author	, Title, D	ate, Pertinen	t Patents,	etc.)		
	A44		Burg 1997		ction of Complete Gene	Structures	in Human Genor	mic DNA," J.	Mol. Biol. 268:78-94,		
	A45		Vilce	k, "Novel inte	rferons," Nature Immur	nology 4(1):	8-9, 2003.				
F.H											
						<u>.</u>		7			
							V-1				
	 										
						··					
						·					
											
Examiner		For	~	11-		ate conside	ered $\frac{1}{2}$	·			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant											